Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12494/41759
Exportar a:
Title: Adjunctive moxifloxacin in the treatment of generalized aggressive periodontitis patients: clinical and microbiological results of a randomized, triple-blind and placebo-controlled clinical trial
Author: Ardila C.M.
Martelo-Cadavid J.F.
Boderth Acosta, G.B,
Ariza-Garcés A.A.
Guzmán I.C.
Email autor: 
Issue Date: 2015
Keywords: antiinfective agent
moxifloxacin
placebo
quinolone derivative
adult
Aggregatibacter actinomycetemcomitans
aggressive periodontitis
bacterial load
Bacteroides
comparative study
controlled study
drug effects
female
follow up
Gingival Hemorrhage
human
isolation and purification
male
microbiology
multimodality cancer therapy
Periodontal Attachment Loss
periodontal pocket
Porphyromonas gingivalis
preventive dentistry
procedures
randomized controlled trial
tooth plaque
treatment outcome
young adult
Adult
Aggregatibacter actinomycetemcomitans
Aggressive Periodontitis
Anti-Bacterial Agents
Bacterial Load
Bacteroides
Combined Modality Therapy
Dental Plaque
Dental Scaling
Female
Fluoroquinolones
Follow-Up Studies
Gingival Hemorrhage
Humans
Male
Periodontal Attachment Loss
Periodontal Pocket
Placebos
Porphyromonas gingivalis
Root Planing
Treatment Outcome
Young Adult
Abstract: Aim The aim of the present study was to evaluate the clinical and microbiological efficacy of moxifloxacin (MOX) in one-stage scaling and root planing (SRP) in treating generalized aggressive periodontitis (GAgP). Materials and Methods Forty subjects were randomly allocated to two treatment groups. The two treatment groups consisted of SRP combined with systemically admi-nistered MOX at the dosage of 400 mg once daily for 7 days or SRP + placebo once daily for 7 days. Subgingival plaque samples were analysed for cultivable bacteria. Results Both groups resulted in significant reduction of probing depth (PD) and clinical attachment level (CAL) compared with baseline (p < 0.0001), and this difference was maintained at 6 months from baseline in both groups. However, subjects receiving MOX showed the greatest improvements CAL, and PD. Subjects in both groups at 6 months displayed the greatest reduction from baseline in frequency of sites with PD =6 mm (p < 0.001), favouring the MOX group. Adjunctive antibiotic protocol reduced subgingival Aggregatibacter actinomycetemcomitans to undetectable levels, after 3 and 6 months, and there was a significant reduction in the levels of Porphyromonas gingivalis and Tannerella forsythia in the MOX group compared to the placebo group. Conclusions The results from this study suggest that moxifloxacin as and adjunct to one-stage full-mouth SRP leads to a better clinical and microbiological advantages compared to mechanical treatment. © 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Type: Artículo
Citation: Ardila CM,Martelo JF,Boderth G,Ariza AA,Guzmán IC. Adjunctive moxifloxacin in the treatment of generalized aggressive periodontitis patients: clinical and microbiological results of a randomized, triple-blind and placebo-controlled clinical trial. J Clin Periodontol. 2015. 42. (2):p. 160-168. .
Other Identifiers: https://doi.org/10.15665/re.v13i2.495
Appears in Collections:Artículos Científicos

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.